We are live on ! Find out more
EPRX

Eupraxia Pharmaceuticals
EPRX

54 hedge funds and large institutions have $157M invested in Eupraxia Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

633% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 3

217% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 6

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

54% more funds holding

Funds holding: 35 → 54 (+19)

51% more capital invested

Capital invested by funds: $104M → $157M (+$53.2M)

9.29% more ownership

Funds ownership: 27.31% → 36.59% (+9.3%)

Holders
54
Holders Change
+19
Holders Change %
+54.29%
% of All Funds
0.66%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
22
Increased
19
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AAA
Affinity Asset Advisors
New York
+$10.4M
2
RG
Redmile Group
California
+$5.63M
3
RCMNY
Rubric Capital Management (New York)
New York
+$5.56M
4
Ameriprise
Ameriprise
Minnesota
+$5.22M
5
IC
Ikarian Capital
Texas
+$4.87M

Top Sellers

Rank Fund Capital Flow
1
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$2.09M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$500K
3
BGC
Beutel, Goodman & Co
Ontario, Canada
-$345K
4
QC
Quadrature Capital
United Kingdom
-$326K
5
XT
XTX Topco
Cayman Islands
-$122K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$1.67M +$1.85M +230,176 New
Marshall Wace
27
Marshall Wace
United Kingdom
$1.14M – – –
CIBC World Market
28
CIBC World Market
Ontario, Canada
$1.09M +$748K +92,900 +160%
Acadian Asset Management
29
Acadian Asset Management
Massachusetts
$671K -$500K -62,166 -40%
Hudson Bay Capital Management
30
Hudson Bay Capital Management
Connecticut
$669K +$743K +92,347 New
TWC
31
TD Waterhouse Canada
Ontario, Canada
$590K +$581K +72,125 +751%
ISL
32
Ingalls & Snyder LLC
New York
$548K -$14.1K -1,750 -2%
1832 Asset Management
33
1832 Asset Management
Ontario, Canada
$434K +$224K +27,862 +87%
Goldman Sachs
34
Goldman Sachs
New York
$384K -$40.1K -4,978 -9%
Raymond James Financial
35
Raymond James Financial
Florida
$366K -$19.4K -2,412 -5%
DP
36
Diadema Partners
New Jersey
$290K +$322K +40,000 New
Bank of Montreal
37
Bank of Montreal
Ontario, Canada
$276K +$8.05K +1,000 +3%
PAP
38
Persistent Asset Partners
Hong Kong
$275K +$305K +37,926 New
Jane Street
39
Jane Street
New York
$254K +$45K +5,588 +19%
Toronto Dominion Bank
40
Toronto Dominion Bank
Ontario, Canada
$237K +$265K +32,898 New
Geode Capital Management
41
Geode Capital Management
Massachusetts
$185K +$94.3K +11,714 +84%
AC
42
AXQ Capital
New Jersey
$114K +$127K +15,760 New
IWC
43
Integrated Wealth Concepts
Massachusetts
$86.9K +$96.6K +12,000 New
TWA
44
TCI Wealth Advisors
Arizona
$79.6K – – –
Two Sigma Investments
45
Two Sigma Investments
New York
$78.2K +$86.9K +10,800 New
ACA
46
Aptus Capital Advisors
Alabama
$76K +$4.03K +500 +5%
GWANC
47
Guardian Wealth Advisors (North Carolina)
North Carolina
$76K +$4.03K +500 +5%
CUAMC
48
China Universal Asset Management Company
China
$72.4K +$80.5K +10,000 New
Morgan Stanley
49
Morgan Stanley
New York
$63.9K +$71K +8,820 New
FDCDDQ
50
Federation des caisses Desjardins du Quebec
Quebec, Canada
$49K – – –
1
2
3

EPRX Hedge Fund Activity: Q1 2026 in Review

54 of the 8,137 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q1 2026, worth a combined $157M — up 51% from $104M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new EPRX positions and 3 closed out — a net gain of 19 holders — while 19 added to existing stakes and 6 trimmed.

The largest buyer was Affinity Asset Advisors, adding an estimated $10.4M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $2.09M sold.

  • 54 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q1 2026, up from 35 in Q4 2025.
  • Funds reported $157M of Eupraxia Pharmaceuticals stock for Q1 2026, up 51% quarter-over-quarter.
  • 22 funds opened new Eupraxia Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +19 holders.
  • The largest Eupraxia Pharmaceuticals buyer in Q1 2026 was Affinity Asset Advisors, an estimated $10.4M added.
  • The largest Eupraxia Pharmaceuticals seller in Q1 2026 was Arrowstreet Capital, an estimated $2.09M sold.

Based on aggregated 13F filings for Q1 2026.